NO20041503L - Pyrimidinoner som melanin konsentrerende hormon reseptor 1 - Google Patents

Pyrimidinoner som melanin konsentrerende hormon reseptor 1

Info

Publication number: NO20041503L
Authority: NO; Norway
Prior art keywords: pyrimidinones; hormone receptor; concentrating hormone; melanin concentrating; melanin
Prior art date: 2001-10-15

Application number

NO20041503A

Other languages

English (en)

Inventor

Anthony Louis Handlon

Andrew J Carpenter

Joel P Cooper

Donald L Hertzog

Yu C Guo

Jason D Speake

David Richard Witty

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-15

Filing date

2004-04-13

Publication date

2004-05-13

2004-04-13 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2004-05-13 Publication of NO20041503L publication Critical patent/NO20041503L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D257/12—Six-membered rings having four nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)

NO20041503A 2001-10-15 2004-04-13 Pyrimidinoner som melanin konsentrerende hormon reseptor 1 NO20041503L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0124627.1A GB0124627D0 (en)	2001-10-15	2001-10-15	Novel compounds
PCT/US2002/032739 WO2003033476A1 (en)	2001-10-15	2002-10-15	Pyrimidinones as melanin concentrating hormone receptor 1

Publications (1)

Publication Number	Publication Date
NO20041503L true NO20041503L (no)	2004-05-13

Family

ID=9923785

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20041504A NO20041504L (no)	2001-10-15	2004-04-13	Lactamderivater som antagonister for humane 11CBY reseptorer.
NO20041503A NO20041503L (no)	2001-10-15	2004-04-13	Pyrimidinoner som melanin konsentrerende hormon reseptor 1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20041504A NO20041504L (no)	2001-10-15	2004-04-13	Lactamderivater som antagonister for humane 11CBY reseptorer.

Country Status (21)

Country	Link
EP (2)	EP1436267B1 (no)
JP (2)	JP2005508966A (no)
KR (2)	KR20040045833A (no)
CN (2)	CN1596247A (no)
AT (2)	ATE349434T1 (no)
BR (2)	BR0213040A (no)
CA (2)	CA2463508A1 (no)
CO (2)	CO5580778A2 (no)
CZ (2)	CZ2004498A3 (no)
DE (2)	DE60217147T2 (no)
ES (2)	ES2283647T3 (no)
GB (1)	GB0124627D0 (no)
HU (2)	HUP0402346A2 (no)
IL (2)	IL161074A0 (no)
MX (2)	MXPA04003534A (no)
NO (2)	NO20041504L (no)
NZ (1)	NZ531911A (no)
PL (2)	PL370587A1 (no)
RU (1)	RU2004110053A (no)
WO (2)	WO2003033480A1 (no)
ZA (2)	ZA200402672B (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0402404A3 (en)	2001-11-26	2011-05-30	Schering Corp	Use of new piperidine-based mch antagonists for producing pharmaceutical compositions suitable for the treatment of obesity and cns disorders
US7084156B2 (en)	2001-11-27	2006-08-01	Merck & Co., Inc.	2-Aminoquinoline compounds
DE10238865A1 (de) *	2002-08-24	2004-03-11	Boehringer Ingelheim International Gmbh	Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7351719B2 (en)	2002-10-31	2008-04-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US20060194871A1 (en) *	2003-04-11	2006-08-31	Barvian Kevin K	Heterocyclic mchr1 antagoists
CN100418965C (zh) *	2003-08-15	2008-09-17	万有制药株式会社	咪唑并吡啶衍生物
KR100747042B1 (ko) *	2003-08-19	2007-08-07	솔젠트 (주)	신물질６-메틸-３-펜에틸-３,４-디히드로-１ｈ-큐나졸린-２-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물
CA2543122A1 (en) *	2003-10-23	2005-05-12	Glaxo Group Limited	3-(4-aminophenyl) thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety
US7592373B2 (en)	2003-12-23	2009-09-22	Boehringer Ingelheim International Gmbh	Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2555824C (en) *	2004-02-13	2011-06-07	Banyu Pharmaceutical Co., Ltd.	Fused-ring 4-oxopyrimidine derivative
DE102004010893A1 (de) *	2004-03-06	2005-09-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7605176B2 (en)	2004-03-06	2009-10-20	Boehringer Ingelheim International Gmbh	β-ketoamide compounds with MCH antagonistic activity
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7524862B2 (en)	2004-04-14	2009-04-28	Boehringer Ingelheim International Gmbh	Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de)	2004-04-14	2005-11-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
CA2589695A1 (en)	2004-12-17	2006-06-22	Eli Lilly And Company	Thiazolopyridinone derivates as mch receptor antagonists
CA2597541A1 (en) *	2005-02-14	2006-08-17	Banyu Pharmaceutical Co., Ltd.	Crystal of 4(3h)-quinazolinone derivative
WO2006118320A1 (ja)	2005-04-28	2006-11-09	Takeda Pharmaceutical Company Limited	チエノピリミドン化合物
WO2007011286A1 (en) *	2005-07-15	2007-01-25	Astrazeneca Ab	Therapeutic agents
BRPI0614995A2 (pt) *	2005-08-31	2010-01-12	Celgene Corp	composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade terapêutica ou profilaticamente eficaz de um composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, e, forma de dosagem unitária única
PT1939204E (pt) *	2005-10-19	2013-03-14	Kissei Pharmaceutical	Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal
US8618115B2 (en)	2005-10-26	2013-12-31	Bristol-Myers Squibb Company	Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7745447B2 (en)	2005-10-26	2010-06-29	Bristol-Myers Squibb Company	Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
JP5193878B2 (ja)	2005-12-21	2013-05-08	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｍｃｈ−１が媒介する疾患における使用のための新規な置換ピラジノン誘導体
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
JP5175228B2 (ja)	2006-02-15	2013-04-03	サノフイ	新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
JP2009526792A (ja) *	2006-02-15	2009-07-23	サノフィ−アベンティス	新規なアザシクリル置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてのそれらの使用
TW200801022A (en)	2006-02-15	2008-01-01	Sanofi Aventis	Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
ATE495157T1 (de)	2006-02-15	2011-01-15	Sanofi Aventis	Neue aminoalkohol-substituierte aryldihydroisochinolinone, herstellungsverfahren und ihre verwendung als medikamente
WO2007142217A1 (ja) *	2006-06-07	2007-12-13	Banyu Pharmaceutical Co., Ltd.	１－フェニルピリドン誘導体
CA2652524A1 (en) *	2006-06-08	2007-12-21	Eli Lilly And Company	Novel mch receptor antagonists
CN101454328A (zh) *	2006-06-08	2009-06-10	伊莱利利公司	新的mch受体拮抗剂
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
JP2010501553A (ja)	2006-08-18	2010-01-21	アストラゼネカアクチボラグ	Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
EP2102208B1 (en)	2006-12-05	2014-04-23	Janssen Pharmaceutica NV	Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
KR20090082484A (ko) *	2006-12-14	2009-07-30	일라이 릴리 앤드 캄파니	5-[4-(아제티딘-3-일옥시)-페닐]-2-페닐-5ｈ-티아졸로[5,4-ｃ]피리딘-4-온 유도체 및 ｍｃｈ 수용체 길항제로서의 이들의 용도
BRPI0806537A2 (pt)	2007-01-10	2014-04-22	Albany Molecular Res Inc	Indazóis substituídos por 5-piridinona
WO2008134480A1 (en) *	2007-04-25	2008-11-06	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DE102007028925A1 (de)	2007-06-22	2008-12-24	Saltigo Gmbh	Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden
ATE544759T1 (de)	2007-07-21	2012-02-15	Albany Molecular Res Inc	5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
JP5632612B2 (ja) *	2007-12-05	2014-11-26	あすか製薬株式会社	ラクタム化合物又はその塩及びｐｐａｒ活性化剤
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
CA2726917C (en)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2321341B1 (en)	2008-07-16	2017-02-22	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2689707A1 (en)	2009-11-16	2011-05-16	Jean-Simon Diallo	Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
KR20120060207A (ko)	2009-08-26	2012-06-11	사노피	신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012036233A1 (ja) *	2010-09-17	2012-03-22	塩野義製薬株式会社	メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR101236188B1 (ko) *	2011-03-10	2013-02-22	한국화학연구원	신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
HUP1100241A3 (en)	2011-05-06	2013-12-30	Richter Gedeon Nyrt	Oxetane substituted pyrimidones
NO3175985T3 (no)	2011-07-01	2018-04-28
TWI478908B (zh)	2011-07-01	2015-04-01	Gilead Sciences Inc	作為離子通道調節劑之稠合雜環化合物
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
BR112015019836A2 (pt)	2013-02-22	2017-07-18	Merck Sharp & Dohme	composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (en)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2015185531A1 (de)	2014-06-05	2015-12-10	Bayer Cropscience Aktiengesellschaft	Bicyclische verbindungen als schädlingsbekämpfungsmittel
EP3394056B1 (en)	2015-12-22	2021-04-14	Shy Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
KR102477316B1 (ko) *	2016-08-12	2022-12-13	바이엘 크롭사이언스 악티엔게젤샤프트	2-(2-디아조늄-6-치환된 페닐)에탄올 염의 폐환에 의한 4-치환된 2,3-디하이드로-1-벤조푸란 유도체의 제조 방법
US10865201B2 (en) *	2016-09-12	2020-12-15	Valo Health, Inc.	Bicyclic compounds useful as GPR120 modulators
CN110225752B (zh)	2016-09-12	2023-05-05	整体健康	用作gpr120调节器的单环化合物
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
CA3066939A1 (en)	2017-06-21	2018-12-27	SHY Therapeutics LLC	Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AR112840A1 (es)	2017-09-29	2019-12-18	Bayer Ag	3- fenilquinazolin-4(3h)-onas sustituidas y sus usos
WO2019063708A1 (en)	2017-09-29	2019-04-04	Bayer Aktiengesellschaft	SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
US12391705B2 (en)	2018-12-19	2025-08-19	Shy Therapeutics, Llc	Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN110563730B (zh) *	2019-07-29	2022-03-25	江苏理工学院	高纯度n10-三氟乙酰蝶酸的制备方法
US12180193B2 (en)	2020-08-28	2024-12-31	Arvinas Operations, Inc.	Accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN113651800B (zh) *	2021-09-07	2022-08-19	山东铂源药业股份有限公司	一种甲磺酸奥希替尼的制备方法
EP4584258A1 (en)	2022-09-07	2025-07-16	Arvinas Operations, Inc.	Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL137227B2 (en) *	1984-03-28	1986-05-31	Univ Lodzki	Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids
RU2200161C2 (ru) *	1996-12-31	2003-03-10	Др. Редди'З Рисерч Фаундейшн	Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
WO2001021577A2 (en) *	1999-09-20	2001-03-29	Takeda Chemical Industries, Ltd.	Melanin concentrating hormone antagonist

2001
- 2001-10-15 GB GBGB0124627.1A patent/GB0124627D0/en not_active Ceased
2002
- 2002-10-15 DE DE60217147T patent/DE60217147T2/de not_active Expired - Fee Related
- 2002-10-15 RU RU2004110053/04A patent/RU2004110053A/ru not_active Application Discontinuation
- 2002-10-15 IL IL16107402A patent/IL161074A0/xx unknown
- 2002-10-15 EP EP02801693A patent/EP1436267B1/en not_active Expired - Lifetime
- 2002-10-15 CA CA002463508A patent/CA2463508A1/en not_active Abandoned
- 2002-10-15 JP JP2003536220A patent/JP2005508966A/ja active Pending
- 2002-10-15 HU HU0402346A patent/HUP0402346A2/hu unknown
- 2002-10-15 ES ES02801692T patent/ES2283647T3/es not_active Expired - Lifetime
- 2002-10-15 PL PL02370587A patent/PL370587A1/xx not_active Application Discontinuation
- 2002-10-15 DE DE60218721T patent/DE60218721T2/de not_active Expired - Fee Related
- 2002-10-15 AT AT02801693T patent/ATE349434T1/de not_active IP Right Cessation
- 2002-10-15 EP EP02801692A patent/EP1442025B1/en not_active Expired - Lifetime
- 2002-10-15 CA CA002463509A patent/CA2463509A1/en not_active Abandoned
- 2002-10-15 KR KR10-2004-7005546A patent/KR20040045833A/ko not_active Withdrawn
- 2002-10-15 CN CNA028235932A patent/CN1596247A/zh active Pending
- 2002-10-15 ES ES02801693T patent/ES2279009T3/es not_active Expired - Lifetime
- 2002-10-15 CZ CZ2004498A patent/CZ2004498A3/cs unknown
- 2002-10-15 AT AT02801692T patent/ATE356119T1/de not_active IP Right Cessation
- 2002-10-15 KR KR1020047005548A patent/KR20050043724A/ko not_active Withdrawn
- 2002-10-15 WO PCT/US2002/032740 patent/WO2003033480A1/en not_active Ceased
- 2002-10-15 BR BR0213040-8A patent/BR0213040A/pt not_active IP Right Cessation
- 2002-10-15 HU HU0402335A patent/HUP0402335A3/hu unknown
- 2002-10-15 MX MXPA04003534A patent/MXPA04003534A/es unknown
- 2002-10-15 MX MXPA04003532A patent/MXPA04003532A/es unknown
- 2002-10-15 NZ NZ531911A patent/NZ531911A/en unknown
- 2002-10-15 PL PL02370138A patent/PL370138A1/xx not_active Application Discontinuation
- 2002-10-15 CN CNA028204522A patent/CN1571774A/zh active Pending
- 2002-10-15 BR BR0213242-7A patent/BR0213242A/pt not_active Application Discontinuation
- 2002-10-15 IL IL16087202A patent/IL160872A0/xx unknown
- 2002-10-15 JP JP2003536216A patent/JP2005510487A/ja active Pending
- 2002-10-15 CZ CZ2004499A patent/CZ2004499A3/cs unknown
- 2002-10-15 WO PCT/US2002/032739 patent/WO2003033476A1/en not_active Ceased
2004
- 2004-04-05 ZA ZA200402672A patent/ZA200402672B/en unknown
- 2004-04-13 NO NO20041504A patent/NO20041504L/no not_active Application Discontinuation
- 2004-04-13 ZA ZA200402814A patent/ZA200402814B/en unknown
- 2004-04-13 NO NO20041503A patent/NO20041503L/no not_active Application Discontinuation
- 2004-04-14 CO CO04034243A patent/CO5580778A2/es not_active Application Discontinuation
- 2004-04-14 CO CO04034241A patent/CO5580779A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA04003532A (es)	2004-07-22
KR20050043724A (ko)	2005-05-11
CZ2004498A3 (cs)	2004-07-14
CO5580779A2 (es)	2005-11-30
CN1571774A (zh)	2005-01-26
IL161074A0 (en)	2004-08-31
PL370138A1 (en)	2005-05-16
CA2463509A1 (en)	2003-04-24
ATE356119T1 (de)	2007-03-15
DE60218721D1 (en)	2007-04-19
RU2004110053A (ru)	2005-10-20
DE60217147D1 (de)	2007-02-08
PL370587A1 (en)	2005-05-30
JP2005510487A (ja)	2005-04-21
CZ2004499A3 (cs)	2004-08-18
ES2279009T3 (es)	2007-08-16
NZ531911A (en)	2004-11-26
JP2005508966A (ja)	2005-04-07
IL160872A0 (en)	2004-08-31
BR0213040A (pt)	2004-10-05
DE60218721T2 (de)	2007-11-15
ES2283647T3 (es)	2007-11-01
CA2463508A1 (en)	2003-04-24
ZA200402672B (en)	2005-04-05
HUP0402346A2 (hu)	2005-02-28
WO2003033476A1 (en)	2003-04-24
KR20040045833A (ko)	2004-06-02
HUP0402335A2 (hu)	2005-02-28
DE60217147T2 (de)	2007-10-31
CN1596247A (zh)	2005-03-16
EP1436267B1 (en)	2006-12-27
CO5580778A2 (es)	2005-11-30
EP1442025A1 (en)	2004-08-04
EP1436267A1 (en)	2004-07-14
ATE349434T1 (de)	2007-01-15
EP1442025B1 (en)	2007-03-07
ZA200402814B (en)	2005-04-13
HUP0402335A3 (en)	2006-02-28
MXPA04003534A (es)	2004-07-22
GB0124627D0 (en)	2001-12-05
BR0213242A (pt)	2004-09-28
NO20041504L (no)	2004-05-13
WO2003033480A1 (en)	2003-04-24

Publication	Publication Date	Title
NO20041503L (no)	2004-05-13	Pyrimidinoner som melanin konsentrerende hormon reseptor 1
DK1379239T3 (da)	2008-01-07	N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
CY1113054T1 (el)	2016-04-13	Παραγωγα διαμινης
CY1106247T1 (el)	2011-06-08	Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
NO20041493L (no)	2004-04-13	Kjemiske forbindelser.
DK1392642T3 (da)	2010-03-08	Hidtil ukendte forbindelser som anti-inflammatoriske, immunmodulatoriske og antiproliferative midler
ATE403429T1 (de)	2008-08-15	Spiropyrazol-verbindungen
UY28290A1 (es)	2004-11-30	Compuestos farmacéuticos novedosos
FI903331A0 (fi)	1990-07-02	Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
CY1111759T1 (el)	2015-10-07	Ενδιαμεσες ενωσεις για την παρασκευη συγκεκριμενων τριαζολοπυριμιδινων ως ρ2τ ανταγωνιστων
BR0206595A (pt)	2004-07-13	Composto, composição farmacêutica, e uso de um composto
DK1456212T3 (da)	2007-04-02	6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
MXPA03009602A (es)	2004-04-02	Analogos de nociceptina.
TR200100885T2 (tr)	2001-08-21	2-Metil-tieno-benzodiazepin formülasyonu
SV2003000981A (es)	2003-07-29	Fenil-heterociclil-eteres ref. pcs10973
EA200601030A1 (ru)	2006-10-27	7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ
DE60039695D1 (de)	2008-09-11	Antifucoidan antikörper
DE60211018D1 (de)	2006-06-01	Fungizide thiazolderivate
PT1140932E (pt)	2004-08-31	Derivados de 1,8-benzonaftiridina
ECSP003511A (es)	2001-01-23	Procedimiento para preparar derivados de 10,11-metanobenzosuberano
ECSP961890A (es)	1997-12-09	Benzotiofenos lipofilos (caso x- 10395)

Legal Events

Date	Code	Title	Description
2006-05-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application